BAVARIAN NORDIC/S (BVNRY) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) posted its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04), Morningstar.com reports. BAVARIAN NORDIC/S had a negative return on equity of 19.43% and a negative net margin of 126.80%. The business had revenue of $19.29 million for the quarter, compared to analyst estimates of $21.15 million.

BAVARIAN NORDIC/S stock traded down $0.06 during midday trading on Thursday, reaching $7.62. The stock had a trading volume of 215 shares, compared to its average volume of 214. BAVARIAN NORDIC/S has a twelve month low of $5.92 and a twelve month high of $10.78. The company has a current ratio of 6.15, a quick ratio of 5.84 and a debt-to-equity ratio of 0.17.

Separately, Zacks Investment Research cut BAVARIAN NORDIC/S from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th.



TRADEMARK VIOLATION WARNING: This piece was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://dakotafinancialnews.com/2019/05/23/bavarian-nordic-s-bvnry-posts-quarterly-earnings-results-misses-expectations-by-0-04-eps.html.

BAVARIAN NORDIC/S Company Profile

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Recommended Story: How to calculate the intrinsic value of a stock

Earnings History for BAVARIAN NORDIC/S (OTCMKTS:BVNRY)

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.